Neogen Chemicals Limited reported a standalone net profit of ₹19.44 crore for the quarter ended June 30, 2026, marking a 36.6% increase from ₹14.23 crore in the corresponding period of the previous year. Revenue from operations rose to ₹252.28 crore from ₹184.58 crore, driven by higher material consumption and inventory adjustments. The Board also granted in-principle approval to raise up to ₹600 crore through equity or debt instruments, signaling strategic capital deployment plans despite a recent credit rating downgrade by Crisil.

The financial results were approved by the Board at its meeting held on July 24, 2026, and reviewed by statutory auditors Chandabhoy & Jassoobhoy. The company confirmed no deviation in the utilization of funds raised through its preferential issue of equity shares earlier in the year. Additionally, the Board appointed CNK & Associates as the internal auditor for FY27 and set August 13, 2026, as the record date for determining eligibility for remote e-voting and final dividend entitlements at the upcoming 37th Annual General Meeting.

Financial Performance Highlights

On a consolidated basis, net profit stood at ₹17.11 crore against ₹10.26 crore in Q1FY25. Consolidated revenue from operations increased to ₹250.29 crore from ₹186.73 crore. The operating margin improved to 19.35% from 15.96%, reflecting better cost management and operational efficiency post-recovery from the March 2025 fire incident at its Dahej SEZ plant.

Capital Structure and Rating Update

Crisil Ratings Limited downgraded Neogen Chemicals’ long-term rating from 'A/Negative' to 'A-/Negative' and short-term rating from 'A1' to 'A2' on July 17, 2026. Consequently, the coupon rate on its outstanding ₹200 crore Non-Convertible Debentures (NCDs) increased from 10.50% per annum to 11.00% per annum effective immediately. Despite the downgrade, the security coverage ratio for the NCDs remained robust at 2.27 times as of June 30, 2026.

The Board authorized raising funds up to ₹600 crore in Indian or foreign currency via Qualified Institutional Placements (QIP), preferential allotment, or other eligible securities. This move aims to strengthen the balance sheet and support growth initiatives across its specialty chemicals and battery chemicals segments.

Insurance Claim Recovery Status

The company continues to recover from the fire incident at its Dahej plant on March 5, 2025. As of June 30, 2026, Neogen Chemicals had received ₹149.38 crore towards insurance claims and scrap sales against a recognized loss of ₹348.16 crore. An additional ₹15 crore was received subsequent to the quarter-end, reducing the outstanding claim receivable to ₹171.63 crore. Management maintains that the remaining balance is fully recoverable.

What the Numbers Show

The divergence between standalone and consolidated margins highlights the impact of inter-segment transactions and subsidiary performance. While standalone operating margins expanded by 84 basis points to 19.09%, consolidated margins saw a sharper improvement to 19.35% from 15.96%. This suggests that subsidiaries are contributing more efficiently to the group’s overall profitability. However, the rising finance costs—up to ₹23.10 crore from ₹14.03 crore year-on-year—indicate increased leverage, partly due to the new NCD issuance. Investors should monitor whether the planned ₹600 crore fund raise will be deployed to reduce interest burden or expand capacity, given the recent rating downgrade.

Neogen Chemicals Limited reported a 67% year-on-year surge in consolidated net profit to ₹17 crore for the quarter ended June 30, 2026 (Q1FY27), driven by record revenues in its Organolithium portfolio and robust performance from its battery materials subsidiary, Neogen Ionics Limited. Consolidated revenue from operations rose 34% to ₹250 crore, while EBITDA jumped 53% to ₹48 crore. The strong financial performance was achieved despite ongoing headwinds from the Dahej plant reconstruction, higher working capital intensity, and geopolitical freight spikes.

The Board of Directors approved the unaudited financial results on July 26, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and recommended by Statutory Auditors Chandabhoy & Jassoobhoy. Additionally, the Board approved raising up to ₹600 crore through a Qualified Institutional Placement (QIP), subject to shareholder and statutory approvals.

Financial Performance

Consolidated revenue reached ₹250 crore in Q1FY27, compared to ₹184.60 crore in Q1FY26. Gross profit expanded by 37% to ₹117 crore. EBITDA grew significantly by 53% to ₹48 crore, reflecting favorable product mix and cost pass-through mechanisms implemented to protect margins against rising raw material and input costs. Net profit after tax (PAT) increased by 67% to ₹17 crore. Consolidated earnings per share (EPS) stood at ₹6.29 per share.

On a standalone basis, revenue rose 37% to ₹252.30 crore, with net profit increasing 37% to ₹19.44 crore. Standalone EBITDA was ₹48.20 crore, up 39% year-on-year, with margins expanding by 30 basis points to 19.1%. Interest expenses increased by 65% to ₹23.10 crore, attributed to higher debt servicing costs following recent credit rating adjustments and increased borrowing to fund capital expenditure.

Neogen Ionics Limited contributed significantly to the group’s growth, with revenue reaching ₹19 crore in Q1FY27, compared to ₹5 crore in the same period last year. This represents over 50% of the subsidiary’s entire prior-year revenue generated in a single quarter.

Expansion Initiatives and Strategic Outlook

Neogen Chemicals is accelerating its footprint in the lithium-ion battery sector through Neogen Ionics Limited. The company has commissioned 200 MTPA capacity for lithium electrolyte salts and additives, with first approval material shipped to customers. Trial production is ongoing for the remaining 1,300 MTPA. A new 1,000 MTPA capacity is targeted for commissioning in H2 FY27, alongside an additional 500 MT intermediate capacity. The 2,000 MT electrolyte plant at Dahej is fully commissioned.

The total estimated project cost for Neogen Ionics’ Dahej Phase 1 and Pakhajan Phase 2 projects stands at ₹1,795 crore. Of this, ₹218 crore was incurred in Q1FY27, bringing cumulative expenditure to ₹1,298 crore. Dahej Phase 1, budgeted at ₹428 crore, is targeted for completion by February 2027, while Pakhajan Phase 2, budgeted at ₹1,367 crore, is expected to be ready by March 2027. Morita’s $20 million equity contribution toward the joint venture remains committed.

What the Numbers Show

The divergence between standalone and consolidated metrics highlights the strategic pivot toward battery materials. While standalone operations delivered steady growth, the consolidated EBITDA surge of 53% versus standalone’s 39% indicates that high-margin contributions from Neogen Ionics are beginning to offset the transitional costs at the core chemical business. The 65% rise in interest expenses underscores the leverage required to fund this aggressive expansion, making the timely execution of the QIP crucial for maintaining balance sheet health. With the Dahej plant reconstruction complete and trial runs underway, the normalization of core operations combined with scaling battery materials output positions the company for significant operating leverage in FY27.